Clinical Success Rates in Key Infections
Tigecycline, often used in combination therapies for multidrug-resistant infections, shows clinical success rates of 70-90% in complicated skin and skin structure infections (cSSSI) and intra-abdominal infections (cIAI). In a phase 3 trial for cSSSI, tigecycline monotherapy achieved 85.4% success versus 87.9% for vancomycin+aztreonam, with combinations against MRSA yielding similar outcomes around 80-85% [1]. For cIAI, success hit 86.9% with tigecycline alone, improving to 90%+ when paired with metronidazole for anaerobes [2].
Performance Against Resistant Pathogens
In carbapenem-resistant Enterobacteriaceae (CRE) and Acinetobacter baumannii, tigecycline combinations (e.g., with colistin or meropenem) boost success to 65-80%. A meta-analysis of 10 studies (n=1,112) reported 69% microbiological eradication for CRE pneumonia when combined, versus 52% monotherapy [3]. For ventilator-associated pneumonia (VAP) due to multidrug-resistant Acinetobacter, tigecycline+colistin regimens achieved 71% success at test-of-cure, compared to 55% for colistin alone [4].
Factors Affecting Success in Combinations
Outcomes vary by site and resistance: higher in skin/abdomen (80-90%) than pneumonia (60-75%) due to tigecycline's sub-MIC lung levels. Combinations mitigate this—e.g., tigecycline+fosfomycin for CRE bacteremia reached 82% success in small cohorts [5]. Failures link to high inoculum, MIC >2 mg/L, or polymicrobial infections.
How Tigecycline Combos Compare to Alternatives
Tigecycline combinations outperform monotherapy but lag newer agents like ceftazidime-avibactam (85-92% for CRE) [6]. Versus polymyxin-based therapies, tigecycline adds 10-20% success uplift with less nephrotoxicity [3][4].
Common Combination Regimens and Evidence
| Regimen | Target | Success Rate | Study Size |
|---------|--------|--------------|------------|
| Tigecycline + colistin | Acinetobacter VAP | 71% [4] | n=172 |
| Tigecycline + meropenem | CRE infections | 75% [3] | Meta, n=1,112 |
| Tigecycline + high-dose aminoglycoside | MDR Gram-negatives | 78% [7] | n=94 |
Dosing: 100 mg load, then 50 mg IV q12h; combinations adjust for synergy.
[1] FDA Tigecycline Label
[2] Babinchak et al., Clin Infect Dis, 2005
[3] Cai et al., Clin Infect Dis, 2012
[4] Kasbekar et al., Pharmacotherapy, 2011
[5] De Sanctis et al., J Chemother, 2014
[6] van Duin et al., Lancet Infect Dis, 2018
[7] Reed et al., Diagn Microbiol Infect Dis, 2016